This study is comparing using rilvegostomig or pembrolizumab with a platinum based chemotherapy. The doctor, subject and study team will not know if the subject is receiving rilvegostomig or pembrolizumab.

After signing consent to agree to join the study, the subject will have lab work and scans of their body to see if they are wll enough to participate. If they begin study treatment, they must come to all study visits. It is important that the subject tell the study team if there has been a change in their medications and how they are feeling. Subjects will continue treatment until the treatment no longer is working, they no longer want to participate of the study doctor feels it is not safe for them to participate any further. Once study treatment is finished, subjects will be followed to see how they are feeling and what new treatments for their cancer they are getting.

$75.00 for each visit completed for a minimum of $300. Compensation may be more if additional visits are completed.

This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the clinical benefit and safety of EFX in subjects with compensated cirrhosis due to NASH/MASH. The study will enroll in 2 cohorts. Cohort 1 will enroll approximately 450 subjects with biopsy-proven compensated cirrhosis due to NASH/MASH. Cohort 2 will enroll approximately 1700 subjects with a clinical diagnosis of compensated cirrhosis due to NASH/MASH.

You will be required to visit the study clinic at specific times points. Laboratory and safety assessments will be completed at each visit. You will need to take the study drug as directed. Study procedures that will be performed include Liver Imaging scans, Liver Stiffness Exams, Electrocardiogram, Bloodwork, Liver Biopsy and an Endoscopy.

The purpose of this Phase 2 clinical trial is to study treating patients with non-muscle invasive bladder cancer (NMIBC) with an investigational drug, Cretostimogene and DDM. Participants will be assigned to either Cohort A or Cohort B depending on whether they have previously been treated with BCG (Bacillus Calmette-Guerin) for NMIBC.

Eligible participants will receive the study drug, Cretostimogene every week for 6 treatments, followed by a maintenance period as directed by the Investigator. For the first 2 years after treatment initiation, participants will be assessed for disease status every 3 months by urine cytology and cystoscopy, with directed TURBT/biopsy (if indicated). CT urogram or MRU will be performed every 6 months. Thereafter, efficacy assessments will be performed at 6-month intervals for up to an additional 2 years

The purpose of this study is to compare accuracy and repeatability of biomechanical metrics between technologies during golf swings. This study also aims to identify differences in swing characteristics between various skill levels and environments.

You will be screened with a Health History Questionnaire via email, online survey, or in-person. You will come to either the Suzy and Jim Broadhurst Golf Teaching and Research Center (GTRC) or the Penn State Golf Courses with your golf clubs to provide consent, collect blood pressure and heart rate, answer golf-related questions, and perform golf-related tasks (full swing shots with various clubs). Various technologies will be used to measure the biomechanics of your swing. The total time of participation is expected to be about 60-90 minutes.

When you have finished the golf-related activites, you will be provided with a brief piece of instruction from one of the Center’s two Class-A PGA Professionals.

This research is being done to investigate the effect of human-machine interface design on promoting driver situation awareness restoration and effective human-AI collaboration under varied takeover situations.

You will complete a set of questionnaires and evaluate the design of the automated driving system by driving on a driving simulator. During the drive, you will be asked to drive in automated mode and focus on tasks unrelated to driving until the system issues a takeover request. The form of the takeover request will change in the experiment. You will be wearing eye tracking glasses while performing the driving task. After the driving tasks, you will complete questionnaires about your perception of the system.

$10/hour

This trial is looking at the progression free survival and overall survival in patients treated with docetaxel alone and those treated with docetaxel and RAS G12X-C

This study has 4 periods: 1. Pre-screening period (to provide your tumor genetic information) 2. Screening period (before you begin the study to see if you qualify for the study). This is when you will have all the testing done to make sure it is safe for you to join the study. it may require several trips to the hospital. 3. Study Treatment period (when you will receive the study treatment; this occurs in 21-day cycles). this is when you will be taking the study medication. For the first cycle of treatment you will need to come to the clinic about 3 times to make sure you are ok while taking the study drug. From cycle 2 onward you will need to come to the clinic twice. 4. Follow-up period (to check on you after your study treatment is finished) and then we will check to see how you are doing every three months. It is important that you come to all of your visits.

The present study will examine the role of different input conditions on the learning of words and morphosyntactic units in a new language. We specifically aim to examine the effects of variables researched in the field: type of knowledge (explicitly stated via pre-training, or incidental; Pellicer-Sánchez et al., 2021), salience (manipulated via input properties; Ellis & Sagarra, 2010) and modality (visual or auditory; Borro, 2021) play on learning outcomes. Our goal is to examine how cognitive processes underlying learning are affected by our manipulations, and the impact on learning outcomes. We hypothesize that pre-training will enhance speakers' ability to detect target vocabulary and structures to be learned. While the literature is mixed on the role of salience, across the experiments described below, we will explore the impact of low-level salience (e.g., text enhanced visually) and psychological salience (the amount of repetition / expectedness of a target items. We will also investigate the less investigated effect of modality.

This is a language learning study. There will be up to two visits to the research lab. Sessions will consist of simple tasks consisting of readings sentences, remembering words, and completing memory tasks. EEG data will be collected via a wearable EEG cap; eye-tracking data will be collected while reading and completing some of the tasks are on a computer.

18 / hour

SR604 is a monoclonal antibody that blocks anticoagulant activity, which improves clotting in patients with the clotting disorders of Hemophilia A & B. This study is looking at treatment options for Hemophilia A & B. There will be 4 cohorts (1B, 2B, 3B & 4B). Our site will be starting study drug SR604 dose escalation with 0.1mg/kg (2B), then 0.2mg/kg (3B) with the final dose 0.4mg/kg (4B). Lower doses will start in the first cohort & dose escalation will continue in subsequent cohorts after a 3-month monitoring period in each cohort. See page 44 of the protocol for patient numbers in each cohort.

Participants will receive subcutaneous SR604 every 4 weeks for 3 months. Total visits to site will be 15. Blood draws will be obtained at each of these 15 visits.

75.00 per visit travel reimbursement

Bilinguals frequently mix languages, even mid-sentence, when communicating with other bilinguals, a practice known as code-switching. This study aims to understand how bilinguals weave together different ways of producing the same sounds, corresponding to the languages they use, when code-switching. Participants will read aloud a list of sentences in Spanish, or in Spanish with switches to English partway through. They will also complete English and Spanish proficiency tasks and a questionnaire about their language background.

Participants will participate in a single session in our lab, lasting about an hour. During this time participants will: Produce words and sentences in Spanish and English. These will be audio recorded. Read and make decisions about words in Spanish and English. Name pictures in Spanish and English. These will be audio recorded. Complete a questionnaire about your language background.

$15

This study is testing whether a lower dose of a medicine called cyclophosphamide (25 mg per kg), given after an allogeneic stem cell transplant, can reduce serious side effects and improve outcomes. We are enrolling people who are receiving a reduced-intensity or non-myeloablative (less intensive) stem cell transplant. We will follow participants for one year after their transplant to see if they stay free from severe graft-versus-host disease (GVHD), cancer relapse, or death. We will also look at overall survival, rates of GVHD, infections, donor cell recovery, and other side effects.

You must attend all scheduled study visits, tell the study doctor about all medications you are taking (including over-the-counter medicines), and let the study team know how you are feeling. Before joining the study, you will have routine health checks. These include breathing tests (called pulmonary function tests, or PFTs) to see how well your lungs work, and a heart scan (MUGA scan or echocardiogram) to see how well your heart is pumping. As part of this study, you will be given a low dose of cyclophosphamide (25 mg/kg) on day +3 and +4 after your stem cell transplant. You will be carefully monitored for any side effects, and the study team will evaluate your risk for graft-versus-host disease (GVHD) and disease relapse.

The purpose of this voluntary research study is to test the effectiveness of the Positive Affect Intervention Program in reducing mental health symptoms for families experiencing financial hardship.

In this study, you and your child will attend some virtual and in-person study visits over 8 months. You will complete some interviews and questionnaires virtually. You will be randomly assigned to either an 8-session prevention program or to receive weekly educational materials to read. You and your child will come to the lab for in-person visits both pre and post program. During these visits, your child will complete some EEG tasks, and you and your child will complete some interaction tasks where your respiratory and heart rate data will be collected. You and your child will also be asked to complete some short daily phone surveys at home.

480 dollars

This study will see if participants who have the addition of saruparib to their treatment will have a longer time period before/if their cancer spreads.

Before participating in the trial, p[otential; participants will need to sign a consent form to have their tumor tested for the BRCA mutation. If the participants have this mutation in their tumor, they will be invited to participate in this trial. While you are receiving treatment you will need to come to the clinic on certain days for treatment, getting safety assessments, collection of blood samples and to see how you are feeling. You will come to the clinic every four weeks. The treatment will last for 24 months

This study is comparing Pembrolizumab in combination with Sacituzumab Govitecan vs. standard treatment for individuals who have drug resistant advanced urolethial cancer

Participants will need to come to the clinic to meet with the study team and to sign a consent form. Once it has been determined that it is safe for you to participate, you will come into the clinic for treatment every 21 days, or depending upon the treatment arm you are assigned. You will continue to come into the clinic for treatment until the medication stops working, you no longer want to participate in the study or the document feels it is not safe for you to continue. You will be followed for up to five years to see how you are doing.

This is a Phase 2b clinical research study, which is investigating the use of 5-Aminolevulinic Acid (5-ALA) combined with a Low-Intensity Diffuse Ultrasound (LIDU) system for Sonodynamic Therapy (SDT) in patients with newly diagnosed glioblastoma. LIDU is the name of the investigational SDT device developed by Alpheus Medical. SDT includes the combination of a sonosensitizing drug, also known as a sonosensitizer, that will only be absorbed by tumor cells, and ultrasound to activate the sonosensitizer and cause damage to the tumor cells. The SDT tested in this study includes the oral drug 5-Aminolevulinic Acid (5-ALA) as an investigational sonosensitizer. This investigational treatment is being tested as a potential treatment for your cancer, SDT has been shown in previous cell and animal studies to potentially have an anti-cancer effect.

In this research study there will be two treatment groups. One treatment group will receive standard of care maintenance temozolomide with 5-ALA + SDT, you will have a 50% of receiving this treatment group. The other treatment group wll receive standard of care maintenance temozolomide with placebo, an oral solution that will look like and taste like 5-ALA but will have no active ingredients in it, and sham SDT, a program will be run on the SDT device that will look and sound the same, but will not deliver ultrasound, you will have a 50% chance of receiving this treatment group. If you are eligible for the study, and agree to participate you will be randomized, like the flip of a coin, to one of the two treatment groups, neither you nor your doctors will know which treatment group you have been assigned.

This trial is designed for patients who are newly diagnosed with multiple myeloma (MM) but who do not want or cannot have an autologous stem cell transplant. Teclistamab and talquetamab have been used alone along with other drugs in the treatment of MM. this study hopes to add either drug to a standard treatment for MM at time of diagnosis to see how effective it is in keeping the MM quiet conpared to standard treatment alone.

Participants must be willing to come to all clinic study visits. The first cycle of treatment the participant will be hospitalized to make sure they do not have any side effects. You will be treated every four weeks as an outpatient until the treatment no longer works. You should tell your study team all side effects you feel and all medication you are taking.

$54.00 per completed visit. A caregiver may receive compensation of the same amount.

The purpose of this study is to investigate the effects of replacing snacks high in saturated fats and added sugars with pecans on blood sugar control, heart health and diet quality in individuals with prediabetes. Participants will be randomized into one of two groups. Group 1 will consume 1.5 oz of pecans per day in place of normally consumed snacks high in saturated fat and added sugars for 16 weeks. Group 2 will be asked to continue consuming their current diet for 16 weeks. Measures will be taken to evaluate blood sugar, heart health and dietary intake at the beginning and 16 weeks later.

• The total time commitment for this study is approximately 4 months. It may take up to 7 months to complete the study from the time that you do the clinic screening visit. • During the study, we will ask you to consume 1.5 oz of pecans per day for 16 weeks, or to use provided gift cards to purchase and consume your usual snacks/diet. • You will be asked to come to the Penn State Research Kitchen on campus once a month for 16 weeks to pick up your pecans or gift cards. • We will draw blood from you several times during the study, once at screening, and on two consecutive days at the start and end of the study (total 5 times). • At the start and end of the study, we will also measure your blood pressure and perform non-invasive tests of artery health. • You will also be asked to wear a continuous glucose monitor (CGM) for 14 days—7 days before the first testing visit and 7 days at the end of the study. The CGM is a small sensor worn on your arm that measures your blood sugar every 15 minutes. You will need to attend a non-fasting visit to have the CGM fitted (2 visits total). • At the start and end of the study, we will ask you to collect 12 saliva samples over two days at home. • At the start and end of the study, we will collect a small hair sample from the back of your head. • You will also be asked to collect a stool sample at the beginning and end of the study (2 total). • Compensation for this study is up to $150

150

To see if the combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus SoC chemotherapy plus trastuzumab plus pembrolizumab is better in treating gastric or gastroesophageal junction cancer

Participants will need to come to the clinic twice before they are able to start study treatment. The first time is to sign a consent form allowing their tumor tissue that has been stored to be spent for testing. This test will look to see if the tissue has changes in it to see if the medication will work. If the tissue has the receptive changes a second consent form will be signed to participate in the study. You will need to have tests done to make sure it is safe for you to participate in the study. If the tests results determine that is it safe, you will begin treatment. The first month of treatment you will need to come to the clinic every week for blood tests and to see how you are feeling. After that you will need to come to the clinic once a month for treatment and blood tests. You will also have scans done at certain time in the study. Those scans will tell the doctor if the study treatment is working to make your cancer go away. You will stay on this treatment until it stops working. After that, you will come back to the clinic for two more visits to see how you are feeling.

To evaluate the long-term safety of AAV2-hAQP1 in participants with radiation-induced late xerostomia

Participants who were on the parent trial and did not receive actual drug will be invited to be treated and then rolled over into long term follow up. For those who were treated with actual drug will roll over into a long term follow up. Long term follow up participants will be followed up monthly for 5 years.

$60 per visit

This is a drug study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL).

All subjects on study will be treated with the medicine blinatumomab. Some subjects will also receive an additional medicine, nivolumab. Subjects will receive treatment on this study for about 1.5-2.5 months. Treatment is divided into 1-2 cycles. Before the start of therapy, patients will have a bone marrow evaluation for Immunophenotyping and will have their bone marrow tested for MRD on Day 36 of cycle 1 and Day 36 of cycle 2 during treatment.

To evaluate the effectiveness of omecamtiv mecarbil in reducing the number of heart failure events or hospitalizations in patients with severely reduced left ventricular ejection fraction <30%.

Participate in about 13 in-person visits over 3 years with bloodwork at each in-person visit, participate in about 9 brief remote phone call visits, questionnaires at 5 of the in-person visits over the first year, first visit electrocardiogram (EKG), first visit Echocardiogram (ECHO) if not completed within the last 6 months, willing to be randomized to take oral study medication or placebo for the duration of the study (about 3 years).

Up to $1,500

This is a human–robot interaction study that will examine how well a robot can learn to perform a coffee-brewing task with help from a human user. Participants will physically correct the robot’s movements when the robot is moving in the wrong way, and will complete a short survey about their experience.

Participants will complete one in-person session. They will stand next to a robotic arm, guide the robot through a coffee-brewing task under different conditions, give physical interactions, and complete a short survey about their experience.

20

This study explores how human emotions influence the choices they make in an interactive game involving monetary prizes. Participants will play 5 repeated rounds of a two-player decision-making game where, in each round, they choose either to cooperate with the other player or act in their own self-interest. The amount of money they earn depends on both their own choice and the choice of the other player in each round. Participants will not be able to see the person that they are playing with because a divider will separate the two. They will also not be told that the other “player” is actually a member of the research team who follows a predetermined pattern of choices in the repeated game. Throughout the study, participants will answer brief questions on their phone about how they are feeling,and they will wear a wrist worn device that measures natural changes in skin conductance, which reflects emotional arousal. By combining these self-reported feelings with physiological signals, the study aims to understand how emotions related to repeated decisions involving cooperation, self interest and monetary incentives.

Participants will attend one in-person session (20-30 minutes). They will wear a wrist device that records skin conductance (EDA) and complete brief online surveys about their mood. They will play a multi-round decision-making game involving monetary earnings with another player. Earnings will depend on both players choices summed over the rounds.

$4-$28

This will compare Dato-Dxd against docetaxel in previously treated advanced or metastatic non squamous NSCLC.

the first visit will be to sign a consent form to test for a specific biomarker in your archived tumor. If you have that biomarker you will then sign a consent form to participate in the study, if you wish. You will need to come to the clinic for bloodwork and scans to make sure it is safe for you to participate. If it is determined that it is safe for you to continue, you will come to the clinic every month for treatment of your cancer. These visit may also include seeing the doctor, having blood work and completing questionnaires.

$1200.00 You will only be compensated for completed visits.

The main purpose of this clinical trial is to determine whether early non-invasive ventilation (NIV) in individuals diagnosed with amyotrophic lateral sclerosis (ALS) is feasible and is associated with improved quality of life, symptoms, and carbon dioxide levels compared to usual care. Study subjects assigned to the “early NIV” group will start NIV earlier than subjects in the usual care group. The study population will included a total of 48 adults diagnosed with ALS at three Neurology ALS clinics in the United States. Subjects will participate in a total of 5 study visits over a 12-month period.

Once eligible, enrolled subjects are assigned to a group (early NIV or usual care), they will attend a total of 5 in person study visits at the ALS clinic over a 12-month period. At Visit 1, subjects will complete questionnaires and assessments and receive the initial study intervention. Follow-up visits at the ALS clinic will take place every 3 months (Visit 2/Month 3; Visit 3/Month 6; Visit 4/Month 9; Visit 5/Month 12) with the completion of questionnaires and assessments plus review of NIV data as applicable.

The purpose of this clinical research study is to learn more about the use of the investigational drug, deucrictibant, for the prevention and treatment of Acquired Angioedema due to C1 Inhibitor Deficiency (AAE-C1INH) attacks. The study consists of a Screening Phase (up to 10 weeks), followed by a 12-weeks Prophylaxis Treatment Phase (Part 1), an On-demand Treatment Phase (Part 2) and an Open-Label On-demand Treatment Phase (Part 3). These are all described below. If you provide your consent to take part in the study and you are declared eligible to participate, your overall study participation will last approximately 15 months (60 weeks). During this study you will be asked to complete an electronic diary daily. At the study visits you will have blood samples collected. Vital signs, EKGs, and physical exams will be performed.

If you decide to take part in this research study, you will have a screening phase (up to 10 weeks), followed by a 12-week Prophylaxis Treatment Phase (Part 1), an On-demand Treatment Phase (Part 2) and an Open-Label On-demand Treatment Phase (Part 3). If you provide your consent to take part in the study and you are declared eligible to participate, your overall study participation will last approximately 15 months (60 weeks). where you will have procedures to determine if you meet the requirements to be in the study. These include a physical exam and an electrocardiogram (ECG) which will measure the electrical activity of your heart. You will also be required to give blood and urine samples. You will also need to complete a daily electronic diary. If you are a woman who can have children, you will also need to take pregnancy tests.

This study examines how speakers change their language use as they age. Sociolinguistic interviews will be used to document and analyze features of English in Pennsylvania. Sociolinguistic interviews will be conducted between the investigator(s) and the participant(s). Participants will be invited to complete the recorded interviews at different intervals in time. The hypothesis is that language use will change as a speaker ages - as social pressures and lifestyle change, so will language.

In this study, the interviewer will ask you a series of questions about your life. The following are some example topics you may be asked about: Personal background (e.g., place of birth, school, work, family, life in Pennsylvania), Leisure, media, everyday life (e.g., hobbies, dreams, sports and social events) Life experiences (e.g., favorite childhood memories, experience during Covid lockdown) Personal beliefs (e.g., spirituality, superstitions) Language (e.g., thoughts about language use and change) The interview will be audio recorded (no video). You will also be asked to complete a background questionnaire so that we can learn more about your life. When filling out the background questionnaire, you are free to skip any questions you prefer not to answer. At the end of the study, we may ask you if you would be interested in being contacted for follow-up interviews.

$20.00

To determine whether the addition of stereotactic ablative radiotherapy (SABR) to the primary tumor in combination with immunotherapy improves outcomes compared to immunotherapy alone in patients with metastatic, unresected, renal cell carcinoma (RCC).

The patient will either get immune therapy (either 2 immune therapy drugs or immune therapy plus a VEGF targeted therapy), or get immune therapy plus radiation therapy. The radiation treatments will be given on 3 different days over the course of 1-3 weeks. Immune therapy will continue until it is no longer working. After the treatment is stopped, the doctor and study team will monitor the patient every 6 months for 5 years after treatment and then annually for 3 years.

This study will look at the safety and effectiveness of cannabigerol (CBG)/cannabidiol (CBD) in the treatment of chemotherapy induced peripheral neuropathy.

You must attend all scheduled study visits, tell the study doctor about all medications you are taking (including over-the-counter medicines), and let the study team know how you are feeling. Patients must come to clinic visits (about every 4 weeks) for health checks, blood tests and surveys, take the hemp oil (CBG/CBD) twice a day for 12 weeks, complete a drug diary, return unused oil on their next visit, and answer phone calls between visits.

$500.00 if substudy completed

This research aims to investigate how memory functions in cognitively healthy individuals by characterizing age-related differences in memory performance and cognitive processes.

Individuals will be asked to complete computer-based and paper-and-pencil tasks with a researcher. These tasks are designed to assess memory and cognition during a single session. This session can be separated at the request of the participant.

$10/hour

The study will evaluate the effectiveness and safety of ICOTROKINRA compared to placebo in participants with moderate to severe Crohn's disease. The participants will be randomized to one of three treatment groups in a 1:1:1 ration and will receive one of the two drug induction regimens versus placebo. At week I-12 of induction treatment (study 1 or study 2 induction), the participants will be evaluated, and if they achieved clinical response or clinical remission, they could then continue treatment in the Maintenance study for 40-weeks. The response to icotrokinra in the study participants will be evaluated by blood draws to test for biomarkers and PK, study symptoms questionnaires (e.g. stool frequency and pain), and colonoscopy with biopsies. They will also have the physical evaluations, ECG, suicidality assessment, pregnancy testing and monitoring of hypersensitivity reactions, along with test for tuberculosis and other infections. In both induction studies and in the maintenance treatment, participants will receive one of the icotrokinra dose or placebo daily oral pill. After the completion of maintenance treatment, the participants could enter open-label extension study for the 4 years. The screening of potential subject will take six weeks, and at least two in-person visits. Eligible participants who signed informed consent can be enrolled in the induction treatment phase, with visit day 0, week 2, week 4, week 8 and week 12. The safety follow-up visit will be held four weeks after the last dose for eligible participants. Dosing will be done on-site during these visits: day 0, and weeks 2, 4, 8, and 12 if starting the maintenance. Biopsy samples will be collected at the screening and week 12 of induction/start of maintenance. During the maintenance phase of treatment for the responders there will be eleven in-person visits including M-0. Colonoscopy exam will be done at M-12, and M-40 weeks to evaluate a response to the treatment.

Participants will be required to sign the informed consent. There will be at least two screening visits on-site. If eligible, participants will be required to attend five in-person visits, comply to the instructions by the study team, have colonoscopy and blood draws done, take medication daily. They will be asked to complete daily diaries of the disease symptoms. Other tests that will be done to ensure safety are ECG, physical exams, target exams, answer questions on tuberculosis and other infections, provide stool samples and urine pregnancy tests if applicable.

$3,122